We saw that the placebo part of the CKD group in the BETonMACE trial had a reduction of eGFR,...

Can we safely assume that that is the norm for <60 eGFR diabetic patients,... over a 3 year period we see a real reduction in eGFR.

We saw a 5% reduction in the phase 2 trials.

If so,... we saw a flat eGFR in the total BETonMACE population,... so if we can assume a fall in eGFR for the CKD placebo group,... we must assume an increase in the treated CKD group to bring the eGFR back to flat for the total BETonMACE population.